GLP-1s and Sleep Apnea in Menopause: The Symptom Nobody Screens You For

Obstructive sleep apnea (OSA) is a condition where the upper airway repeatedly collapses during sleep, briefly cutting off breathing. Each event — an apnea (full stop) or hypopnea (partial collapse) — pulls you out of deep sleep, spikes your heart rate, and drops your blood oxygen. It can happen dozens of times an hour, all night, without you ever consciously waking.

Menopause is an independent risk factor for it, and the reasons are mechanical:

Estrogen and progesterone maintain airway tone. Progesterone in particular is a respiratory stimulant — it increases the drive to breathe and helps keep the dilator muscles of the upper airway active during sleep. Estrogen supports muscle tone and reduces airway inflammation. When both decline, the airway becomes floppier and more collapsible.

Body composition shifts. Menopause drives fat redistribution toward the trunk and neck — and [visceral fat gain in midlife](/blog/glp1-and-visceral-fat-in-menopause-targeting-belly-fat) is well documented. Fat deposition around the neck and pharynx directly narrows the airway.

Sleep architecture changes. Less deep sleep and more fragmented sleep make the airway more vulnerable during the lighter stages when muscle tone is lowest.

The epidemiology reflects this. Before menopause, OSA is far more common in men than women. After menopause, the gap narrows dramatically — postmenopausal women have been found to have several times the risk of premenopausal women in cohort studies, with hormone therapy users showing lower rates than non-users.

So if you've been lying awake at 3am wondering why you feel destroyed despite 'sleeping' eight hours — this is a hypothesis worth taking seriously.

Because the diagnostic picture in most clinicians' heads is a man.

The classic OSA presentation — an overweight middle-aged man who snores like a chainsaw and falls asleep at his desk — is a real pattern. It is also the pattern that gets screened for. Women frequently do not present that way.

How OSA actually presents in midlife women:

• •Fatigue rather than overt daytime sleepiness. Women are more likely to say 'I'm exhausted' than 'I fall asleep watching TV.'
• •Insomnia. Difficulty staying asleep, frequent night waking — which gets treated as insomnia rather than investigated as a breathing problem.
• •Morning headaches.
• •Low mood, anxiety, and irritability. Often diagnosed as depression.
• •Brain fog and memory complaints.
• •Less dramatic snoring, and often no snoring reported at all — particularly in women who sleep alone.

Now look at that list again and notice what it collides with: every single one of those symptoms is also on the menopause symptom list. Fatigue. Insomnia. Brain fog. Mood changes. Irritability.

This is the trap. A 52-year-old woman reports exhaustion, poor sleep, brain fog and low mood. The obvious answer is menopause. It's the right answer often enough that nobody looks further — and a treatable, cardiovascularly dangerous condition goes undiagnosed for years while she's told to try meditation.

Menopause and OSA are not mutually exclusive. Menopause *causes* OSA. Being in perimenopause doesn't rule sleep apnea out — it makes it *more* likely. If your [menopause fatigue](/blog/menopause-fatigue-why-youre-exhausted-and-what-helps) and [brain fog](/blog/menopause-brain-fog-why-it-happens-and-what-helps) aren't improving with treatment, this is the question to ask.

SURMOUNT-OSA (published in the New England Journal of Medicine, 2024) was a landmark trial, because until it ran, no medication had ever been shown to treat obstructive sleep apnea. The only real options were CPAP, weight loss, positional therapy, and surgery.

The design. Two parallel trials enrolled adults with moderate-to-severe OSA and obesity — one group who could not or would not use CPAP, and one group already using it. Participants received tirzepatide (up to 15mg weekly) or placebo for 52 weeks.

The primary endpoint was change in the apnea-hypopnea index (AHI) — the number of breathing interruptions per hour of sleep. AHI is how OSA severity is graded:

• •5-15 events/hour = mild
• •15-30 events/hour = moderate
• •30+ events/hour = severe

The results. Tirzepatide reduced AHI by up to 29.3 events per hour, compared with 5.5 events per hour on placebo. Participants started with an average AHI in the severe range. That's not a marginal improvement — for a substantial share of participants, it was the difference between severe OSA and mild or resolved OSA. A meaningful proportion reached remission or near-remission by the trial's criteria.

Blood pressure, oxygen saturation, and inflammatory markers improved alongside it.

Why it works: primarily through weight loss — reducing fat around the airway and in the trunk reduces mechanical collapse. There may be additional mechanisms, but the weight-loss pathway is the dominant one and the honest explanation.

The important caveat. SURMOUNT-OSA studied people with OSA and obesity. If your sleep apnea is driven by airway anatomy rather than weight — a small jaw, a narrow airway, large tonsils — a GLP-1 is unlikely to fix it. This is a real treatment for a specific population, not a universal one.

That's a conversation with your doctor, not a decision to make from an article. But here's the honest framing.

The case for it is strong if:

• •You have diagnosed OSA and obesity (or significant excess weight), and
• •You're in perimenopause or postmenopause, and
• •You have other metabolic reasons to consider a GLP-1 — insulin resistance, prediabetes, elevated cardiovascular risk.

In that situation you're treating four things with one intervention: the OSA, the weight, the [insulin resistance that menopause worsens](/blog/glp1-menopause-insulin-resistance-the-connection), and cardiovascular risk. SELECT (NEJM 2023) found semaglutide reduced major adverse cardiovascular events by 20% in people with obesity and existing cardiovascular disease.

The case is weaker if:

• •Your OSA is anatomically driven rather than weight-driven. Weight loss won't widen a structurally narrow airway.
• •You're at a healthy weight. GLP-1s are not indicated for OSA in the absence of excess weight, and the trial evidence doesn't support it.

Critical safety point: a GLP-1 is not a replacement for CPAP — and you must not stop CPAP on your own. If you're on CPAP, keep using it. Any change to OSA treatment should come from a sleep physician after a repeat sleep study documents actual improvement. Untreated OSA carries real cardiovascular consequences, and 'I feel better' is not an adequate substitute for measurement.

What about HRT? Observational data suggests hormone therapy users have lower OSA rates than non-users, which is mechanistically plausible given progesterone's respiratory-stimulant effect. But HRT is not an established OSA treatment, and there's no trial evidence supporting prescribing it for that purpose. It may help; don't count on it as your treatment. Our guide to [HRT and GLP-1 together](/blog/hrt-and-glp1-together-menopause-weight-loss-synergy) covers combining them.

And a practical note: as your weight drops, your OSA severity can change, which means your CPAP pressure settings may need re-titration. This is a good problem — but it's one that requires a follow-up appointment, not silent self-adjustment.

Easier than you'd think, and the barrier is almost always getting someone to take you seriously enough to order it.

The two testing options:

Home sleep apnea test (HSAT). A small device you wear overnight in your own bed — a finger sensor, a chest band, sometimes a nasal cannula. Simple, cheap, increasingly common, and adequate for diagnosing moderate-to-severe OSA in people without complicating conditions.

In-lab polysomnography. The full overnight study, with EEG, breathing, oxygen, heart rate, and limb movement monitoring. More sensitive, better at picking up mild OSA — which matters, because women are more likely to have milder or REM-predominant apnea that a home test can miss. If you have a strong clinical picture and a negative home test, ask about a lab study before accepting the negative.

How to actually get referred. Bring specifics, not vibes:

• •Track two weeks of data. Bedtime, wake time, how many times you wake, how you feel on waking, morning headaches, daytime energy.
• •Ask your partner to observe. Snoring, gasping, choking, pauses in breathing. A witnessed apnea is one of the strongest predictors there is.
• •Say the specific words. 'I would like to be screened for obstructive sleep apnea. I understand that menopause increases the risk and that it's underdiagnosed in women.' Vagueness gets deflected; specificity gets referrals.
• •Push back on 'it's just menopause.' The correct response is: 'Menopause increases sleep apnea risk. I'd like to rule it out.'

Red flags that warrant urgency: witnessed breathing pauses, waking gasping or choking, morning headaches, uncontrolled high blood pressure, falling asleep while driving.

If you're already on a GLP-1 and your sleep is still terrible, that's also worth investigating — GLP-1s can improve OSA, but they're not guaranteed to resolve it, and other things (night sweats, [restless nights in menopause](/blog/sleep-on-glp1-during-menopause-fixing-restless-nights)) can be running in parallel.

The fatigue you've been told to live with may have a name, a test, and a treatment.